1 / 37

Management of Testicular GCT

Management of Testicular GCT . By Dr.Turky Al- Mouhissen Chief Urology Resident – WR R5 Urology – KKNGH. Relapse 17%, median 15/12, O.S. 98%. Recurrence rate 9%. 15-20% of stage 1 will have retroperitoneal L.N. disease. 25 Gy 5yr SR >95% Dogleg Paraortic Strip. 30-35 Gy

joshwa
Télécharger la présentation

Management of Testicular GCT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Management of Testicular GCT By Dr.Turky Al-Mouhissen Chief Urology Resident – WR R5 Urology – KKNGH

  2. Relapse 17%, median 15/12, O.S. 98% Recurrence rate 9% 15-20% of stage 1 will have retroperitoneal L.N. disease 25 Gy 5yr SR >95% Dogleg Paraortic Strip

  3. 30-35 Gy 5y surv. 80%

  4. Sheet of tissue Around great vessels 27%

  5. Residual mass post chemo. : • 27 % Seminoma: >3cm, well discrete Excision • 10-19% Nonseminoma: low threshold for surgical excision, combined with RPLND Surgical excision in Nonseminoma can be avoided if: >90% response of tumor to chemo. With absence of teratoma in primary tumor

  6. Nonseminomatous Germ Cell tumors Relapse rate 28% >60% in Retroperi. If Relapsed chemo / pN2 20-25% clinical stage 1 is understaged In stage 1, 30% have Retroperi. disease 5-10% relapse

  7. Back pain • Contralateral / multifocal disease • High tumor markers • Suprahilar L.N. 48% Relapse rate

  8. International germ cell classification system for testicular ca.

  9. (Good & Intermediate Risks) Response rate 90-95% 20% disease free Post salvage chemo residual mass: 50% Ca. 40% Teratoma 10% fobrosis Response rate 50% Residual mass post therapeutic chemo: 10% Ca., 50% Teratoma, 40% Fibrosis

  10. RPLND

  11. Rt side: • Interaortocaval, preaortic & precaval, paracaval, Rt iliac • Lt side: • Paraortic, preaortic, interaortocaval, Lt iliac

  12. Bilateral RPNLD

  13. B/L RPLND • Transabdominal approach • 2-3 hours procedure • Negligible mortality, morbidity 5-25% • Morbidity related to : • Atelactasis • Pneumonitis • Ileus • Lymphocele • pancreatitis

  14. Long term morbidity of B/L RPLND: • Loss of antigrade ejaculation • infertility

  15. Modified (Template) RPLND Interaortocaval & Ipsiplateral L.N. betw. Renal vessels & bifurcation of Common Iliac artery Avoid contralateral dissection below IMA Time consuming Require steeper learning curve Ejaculation preserved in 100% Fertility noted in 75%

  16. lymphadenectomy • Dissection of renal veins to the IVC • Gonadal vessels ligated • Tributaries of Renal vein in left side ligated • Adrenal • Gonadal • Lumbar • Anterior split on the surfae of the aorta is done inferiorly to the level of the bifurcation of iliac art.

  17. The Split & Roll technique

  18. Renal art. Skeletonized • Gonadal art. Ligated to prevent subadventetialhemtoma if they are avulsed • After completing B/L dissection: • Aorta. IVC, Renal vessels should be skeletonized • Ant. Spinouslig. Visible • Stumps of Rt. & Lt. gonadal vessels & IMA are visible • Irrigation with warm water • Lymphostasis & hemostasis secured

  19. Post. Parietal peritoneum loosly approx. • Fascia closed • Postoperative tachycardia is common due to sympathaticdishcarge

  20. Nerve sparing technique

  21. Scrotal violation • Suboptimal approaches to testicular neoplasms • 4-17% • Scrotal orchiectomy • Transscrotal biopsy • Fine-needle aspiration

  22. A recent metaanalysis of 206 pts reported • local recurrence rate 2.9% compared to 0.4% treated with inguinal approach • no difference in systemic relapse or survival rate • No advantage to adjuvant chemo. (capelouto et al 1995)

  23. Recommendations for pts with scrotal violation : • In low stage seminoma, radiation portals should include ipsilateral groin & scrotum • Low stage NSGCT, scrotal scar should be widely excised with spermatic cord remnant at the time of RPLND • Pts with clinical stage 1 NSGCT & scrotal violation are not good candidates for surveillance • Pts treated with full dose platinum based regimen should have the cord stump removed at RPLND • Extensive groin dissection / hemiscrotectomy not required due absence of local relapse after systemic treatment

  24. Note: Pts with h/o herniorrhaphy / prior orchidopexy in stage 1-2 seminoma, should have contralateral inguinal region to be irradiated with contralateral testicle shielded

  25. chemotherapy • Adjuvant / Therapeutic Chemo. is BEP= bleomycin + Etoposide + Cisplatin • 3 cycles of BEP = 4 cycles EP in Therapeutic Chemo. • Salvage Chemo. is VIP= Vinblastine + Ifosfamide + Cisplatin

  26. S/E: • Bleomycin: Skin toxicity • Most frequent S/E, reported approximately 50% of treated patients • Erythema, rash, striae, vesiculation, hyperpigmentation, skin tenderness • Hyperkeratosis, nail changes, alopecia, pruritus, and stomatitis, scleroderma • Usually late, occurs at 2nd and 3rd week of treatment Pulmonary fibrosis Hypersensitivity reaction CVS S/E such as MI, CVA, Thrombotic events Gastrointistinal S/E (Rare)

  27. Bleomycin Pulmonary Toxicty (BPT) : • Occurs in 6.8% • Mortality rate 1% • Risks • >40 year old • GFR<80 • Advanced • Cumulative dose effect • Rx • Keep hypovolemia • Keep low Fi O2

  28. Etoposide: Secondary leukemia (dose dependent) Alopecia Myelodepression Mild renal impairment • Cisplatin: Nephrotoxicity Neurotoxicity Ototoxicity Nausea & vomitting

  29. Vinblastine: Generally not lasting more than 24 hours Leukopenia, myelosuppression Alopecia Gastrointestinal symptoms Parasthesia • Ifosfamide: Hrgiccysitis (should use Mesna before it to prevent it) Mild renal insuffeciency (usually transient), 4-7% Myelosuppression

  30. Thank You

More Related